Remdesivir (RDV) was the first Food and Drug Administration (FDA)-approved medication
for COVID-19, with discordant data on efficacy in reducing mortality risk and disease …

Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for
recommending its use for the treatment of moderate-to-severe disease is still controversial …

Purpose This review was aimed to synthesise the best available evidence on the
effectiveness and safety of remdesivir in the treatment of moderate to severe COVID-19 …

Aim To evaluate the association of remdesivir use and the survival of hospitalized patients
with coronavirus disease 2019 (COVID-19). Methods We retrospectively reviewed the …

Introduction Remdesivir exerts positive effects on clinical improvement, even though it
seems not to affect mortality among COVID-19 patients; moreover, it was associated with the …

Objective Controversial results on remdesivir efficacy have been reported. We aimed to
report our real-life experience with the use of remdesivir from its availability in Spain …

Objectives The use of remdesivir (RDV) as the first drug approved for coronavirus disease
2019 (COVID-19) remains controversial. Based on the Lean European Open Survey on …

Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-
hospital all-cause mortality in a lar Page 1 © The Author(s) 2021. Published by Oxford University …

Objectives Remdesivir is one of the most widely recommended and used medications for
COVID-19 treatment. However, different outcomes have been reported for hospitalized …

Background There is an urgent need to understand the real-world effectiveness of
remdesivir in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …